Pds biotech announces fda clearance of ind application for combination of versamune® muc1 and pds01adc to treat metastatic colorectal cancer

Phase 1/2 trial evaluating the proprietary combination to be run under crada with the national cancer institute second versamune ® platform candidate targets muc1-positive solid tumors u.s. patent #12,201,685 covering methods of using combinations of the versamune ® platform and various immunocytokines, including pds01adc recently issued princeton, n.j., march 13, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the u.s. food and drug administration has cleared its investigational new drug (“ind”) application filed in january 2025 to evaluate a combination of versamune® muc1 (formerly pds0103), its novel investigational muc1-targeted immunotherapy candidate + pds01adc to treat muc1-positive unresectable, metastatic colorectal carcinoma (“mcrc”) in patients who failed previous treatment.
PDS Ratings Summary
PDS Quant Ranking